MetaCap

Avantor (AVTR) vs 10x Genomics (TXG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

10x Genomics (TXG) has outperformed Avantor (AVTR) over the past year, gaining 182.4% versus a gain of 28.8%. Over five years, AVTR leads with a -62.5% price change compared with -65.2% for TXG. Avantor is the larger company by market cap ($10.06 billion vs $6.81 billion), about 1.5 times the size, while 10x Genomics is growing revenue faster (+5.2% vs -3.4%).

On valuation, Avantor trades at a lower forward P/E (16.7x vs 597.7x for 10x Genomics). 10x Genomics converts more of its revenue into profit, with a net margin of -6.8% versus -8.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVTR+28.82%TXG+182.44%
+456%+199%-59%
Nov 21, 20251 yearNov 20, 2026
AVTR-62.58%TXG-65.46%
+11%-44%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVTR versus TXG key metrics
MetricAVTRTXG
Share price$14.84$51.80
Market cap$10.06B$6.81B
1-day change-1.85%-9.72%
YTD return+29.49%+217.60%
1-year return+28.82%+182.44%
5-year return-62.54%-65.20%
P/E ratio (TTM)29.68—
Forward P/E16.73597.67
EPS (TTM)$0.50$-0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$6.55B$642.82M
Revenue growth (YoY)-3.41%+5.25%
Net income (latest FY)$-530.20M$-43.54M
Gross margin32.65%69.05%
Operating margin-3.76%-9.49%
Net margin-8.09%-6.77%
52-week high$17.45$102.81
52-week low$7.27$15.18
Distance from 52-week high-14.96%-49.62%
Analyst consensusholdbuy
Avg. price target upside+16.91%+31.54%
Average volume8.77M3.36M
Shares outstanding677.62M121.46M
Employees13,5001,178
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TXG has outperformed AVTR by 153.6 percentage points over the past year.
  • 10x Genomics grew revenue faster in its latest fiscal year (+5.25% vs -3.41%).

About Avantor

AVTR stock →

Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.

Industrials · Biotechnology: Laboratory Analytical Instruments · 13,500 employees

About 10x Genomics

TXG stock →

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.

Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees

AVTR vs TXG FAQ

Which is bigger, Avantor or 10x Genomics?

Avantor (AVTR) is larger, with a market capitalization of $10.06B compared with $6.81B for 10x Genomics (TXG).

Which stock has performed better over the past year, AVTR or TXG?

TXG returned +182.44% over the past 12 months, compared with +28.82% for AVTR (price return, excluding dividends). Past performance does not predict future results.

Are Avantor and 10x Genomics in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons